SynthesisPloS one2016
Antidepressants in the Treatment of Functional Dyspepsia: A Systematic Review and Meta-Analysis.
Synthesis in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 4 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- A Clinical Practice Update for the Management of Patients With Disorders of Gut-Brain Interaction and Altered Food Intake Behavior.Neurogastroenterology and motility · 2026Guideline
- Prokinetics for the treatment of functional dyspepsia: an updated systematic review and network meta-analysis.BMC gastroenterology · 2023Pooled it
- Evidence-based clinical practice guidelines for functional dyspepsia 2021.Journal of gastroenterology · 2022Guideline
- Pooled it
- Insights Into Functional Dyspepsia and Gastroparesis - Western Versus Asian Perspectives.Journal of neurogastroenterology and motility · 2025Review
- Managing dyspepsia as a generalist.Singapore medical journal · 2025Article
- Comprehensive Treatment of Functional Dyspepsia Using Traditional Chinese Medicine: A Review Based on Pathophysiological Perspectives.Drug design, development and therapy · 2025Review
- Clinical Trial: Efficacy of Mosapride Controlled-release and Nortriptyline in Patients With Functional Dyspepsia: A Multicenter, Double-placebo, Double-blinded, Randomized Controlled, Parallel Clinical Study.Journal of neurogastroenterology and motility · 2024Article
- Management of dyspepsia and Helicobacter pylori infection: the 2022 Indonesian Consensus Report.Gut pathogens · 2023Review
- Pharmacological Treatment of Functional Dyspepsia: An Old Story Revisited or a New Story to Be Told? A Clinical Review.GE Portuguese journal of gastroenterology · 2023Review
- Comparative Efficacy of Various Pharmacological Interventions in the Treatment of Functional Dyspepsia: A Network Meta-Analysis.Digestive diseases and sciences · 2022Article
- Article
- Review
- Clinical Practice Guidelines for Functional Dyspepsia in Korea.Journal of neurogastroenterology and motility · 2020Review
- Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future.Breast cancer : basic and clinical research · 2020Review
- Efficacy of serotonin receptor agonists in the treatment of functional dyspepsia: a meta-analysis.Archives of medical science : AMS · 2019Review
- Management of functional dyspepsia: state of the art and emerging therapies.Therapeutic advances in chronic disease · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntidepressants have been empirically used in the treatment of functional dyspepsia (FD). However, results from recent clinical trials investigating their efficacy are conflicting. The aim of this study is to evaluate the efficacy of antidepressants in the management of FD in adults.
methodsDatabases of MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials and BIOSIS Previews were searched for all randomized controlled trials (RCT) investigating efficacy of antidepressants in the management of FD in adult patients. Data of overall symptom unimproved and adverse events were compared between the antidepressants and placebo group.
resultsThe search strategy identified 432 citations. Of those, eight RCTs met the inclusion criteria and were included in the meta-analysis. The pooled relative risk (RR) of symptom unimproved with tricyclic antidepressants (TCAs) versus placebo was 0.76 (95% CI: 0.62 to 0.94, P = 0.01; I2 = 0%, P = 0.39). By contrast, selective serotonin reuptake inhibitors (SSRIs) did not show a benefit over placebo (RR = 1.00, 95% CI: 0.86 to 1.17, P = 0.95; I2 = 0%, P = 0.82). Adverse events were significantly more frequent among patients receiving antidepressants than those receiving placebos (RR = 1.64, 95% CI: 1.14 to 2.35, P = 0.007).
conclusionTCAs but not SSRIs, are effective in the treatment of FD, but antidepressants were also associated with more adverse events compared with placebo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.